跳至主要内容
临床试验/NCT02832206
NCT02832206已完成不适用

EndoMaze HYBRID project-a Detailed Assessment of Efficacy and Safety of Hybrid Ablation of Persistent and Long-standing Persistent Atrial Fibrillation

Charles University, Czech Republic1 个研究点 分布在 1 个国家目标入组 59 人开始时间: 2016年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
59
试验地点
1
主要终点
sinus rhythm (The Reveal LINQ Insertable Cardiac Monitoring System)

研究概览

简要总结

This study evaluates in detail efficacy and safety (including neurological safety) of hybrid ablation of stand-alone, persistent and long-standing persistent atrial fibrillation (AF). An implantable ECG monitor will be implanted to all patients for rhythm monitoring. Neurological safety will be assessed by cerebral magnetic resonance, neuropsychological examination and periprocedural transcranial Doppler measurement.

详细描述

Hybrid ablation (i.e. surgical thoracoscopic ablation, followed by catheter endocardial ablation) represent a new treatment option for patients with atrial fibrillation.

60 patients will undergo a two-stage, hybrid ablation, all of them will have an ECG monitoring device implanted and will be followed for up to three years. Neurological safety of both surgical and catheter procedures will be assessed by three examinations. Magnetic resonance will be performed before surgery, 5 days after surgery and at the 180 days visit to search for (subclinical) cerebral ischemia. Complex neuropsychological examination will be performed before surgery, afer 1 month after surgery and at 180 days visit to search for changes in cognitive functions, behavioral functions etc. Transcranial Doppler will be performed during surgical and catheter ablation to detect microembolic signals.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients age > 18 years
  • Patients with persistent/long-standing persistent AF according to the standard EHRA definition.
  • Patients with symptomatic AF that is refractory to at least one antiarrhythmic medication.
  • Absence of significant structural heart disease (dilated cardiomyopathy, hypertrophic cardiomyopathy, valvular heart disease, untreated coronary artery disease)
  • Ability to sign an informed consent

排除标准

  • Paroxysmal AF
  • AF secondary to a reversible cause (i.e., thyreopathy, etc.)
  • Indication for open-heart surgery (coronary artery bypass grafting, valve surgery, etc.)
  • Severe left ventricle dysfunction that is clearly caused by some other cardiac disease (dilated cardiomyopathy, ischaemic heart disease, etc.) where the AF is clearly of secondary etiology
  • Known severe pericardial and pleural adhesions (e.g., history of cardiac surgery)

结局指标

主要结局

sinus rhythm (The Reveal LINQ Insertable Cardiac Monitoring System)

时间窗: 1 year

Number of patients with sinus rhythm, without detections of atrial arrhythmias (episodes longer than 30 seconds)

次要结局

  • periprocedural complications - surgery(30 days)
  • neurological safety (cerebral magnetic resonance (MR), neuropsychological changes - multiple questionnaires, Transcranial Doppler)(180 days)

研究者

发起方
Charles University, Czech Republic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Petr Budera

M.D., Ph.D.

Charles University, Czech Republic

研究点 (1)

Loading locations...

相似试验